The main reason for the development of severe pneumonia in patients with COVID‑19 is apparently injury of the endothelium by the virus and the immune system, which leads to the development of massive microthrombosis. We believe that it is very important to prescribe anticoagulants to COVID-19 patients as early as possible and to administer prolonged low doses of glucocorticoids at certain indicators. These treatment regimens are expected to reduce the mortality caused by COVID‑19. Perhaps it is necessary to be very careful about the administration of IL-6 inhibitors. We assume that the main indicators for the administration of IL-6 inhibitors are the following indicators: CRP > 150 mg/L, IL-6 in the blood > 40 pc/mL, procalcitonin < 0.5 μg/L. To confirm our hypotheses, a large-scale study is required.